Evidence map›Paper›PMID 40153223›Full record

ArticleClinical journal of gastroenterology2025

Advanced intrahepatic cholangiocarcinoma successfully treated with combined immunotherapy: focusing on the tumor immune microenvironment.

Mayu Omoto, Katsutoshi Sugimoto, Yutaka Kurebayashi, Tatsuya Kakegawa, Hiroshi Takahashi, Takuya Wada, Hirohito Takeuchi, Toshitaka Nagao, Yuichi Nagakawa, Takao Itoi

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mayu OmotoDepartment of Gastroenterology and Hepatology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 1600023, Japan.
Katsutoshi SugimotoDepartment of Gastroenterology and Hepatology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 1600023, Japan. sugimoto@tokyo-med.ac.jp.ORCID http://orcid.org/0000-0001-6271-7806
Yutaka KurebayashiDepartment of Pathology, Keio University School of Medicine, Tokyo, Japan.
Tatsuya KakegawaDepartment of Gastroenterology and Hepatology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 1600023, Japan.
Hiroshi TakahashiDepartment of Gastroenterology and Hepatology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 1600023, Japan.
Takuya WadaDepartment of Gastroenterology and Hepatology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 1600023, Japan.
Hirohito TakeuchiDepartment of Gastroenterology and Hepatology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 1600023, Japan.
Toshitaka NagaoDepartment of Anatomic Pathology, Tokyo Medical University, Tokyo, Japan.
Yuichi NagakawaDepartment of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Tokyo, Japan.
Takao ItoiDepartment of Gastroenterology and Hepatology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 1600023, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 61-year-old female patient with advanced intrahepatic cholangiocarcinoma diagnosed based on imaging and tumor biopsy findings was treated with combination therapy comprising gemcitabine, cisplatin, and durvalumab. After eight cycles of therapy comprising gemcitabine, cisplatin, and durvalumab and two subsequent cycles of maintenance immunotherapy, significant tumor shrinkage enabled conversion surgery with R0 resection. The tumor immune microenvironment has a critical role in predicting the efficacy of combined immunotherapy in some types of cancer; however, its role in advanced intrahepatic cholangiocarcinoma remains largely unclear. In the current case, the tumor exhibited increased infiltration of CD8 T cells before treatment, and significant increase in CD8 T-cell infiltration, decrease in Treg/CD8 ratio, and development of tertiary lymphoid structures were observed after treatment. Pretreatment tumor immune microenvironment analyses may predict treatment outcomes and optimize strategies for advanced intrahepatic cholangiocarcinoma. Therapy comprising gemcitabine, cisplatin, and durvalumab and immune-based approaches may enhance personalized medicine for patients with advanced intrahepatic cholangiocarcinoma.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBile Duct NeoplasmsCholangiocarcinomaImmunotherapyTumor MicroenvironmentAntibodies, MonoclonalCD8-Positive T-LymphocytesCisplatinCombined Modality TherapyDeoxycytidineFemaleGemcitabineHumansMiddle AgedAntibodies, MonoclonalCisplatinDeoxycytidinedurvalumabGemcitabineConversion surgeryImmune checkpoint inhibitorTumor-infiltrating lymphocytes

Identifiers

PMID40153223
PMCPMC12095400

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.